- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07848477
PROMOTE: Effects of 5-HT4 Agonism on Cognition and Sleep in Peopl With Low Mood (PROMOTE)
Investigating the Effect of 5-HT4 Receptor Agonism on Cognition and Sleep in People With Low Mood
Serotonin is a chemical in the brain that plays an important role in mood, sleep, and other functions. It works by attaching to different types of serotonin receptors on brain cells. These receptors act like "locks", with serotonin acting like a "key". Different types of serotonin receptors have different effects in the brain.
Prucalopride is a licensed medication used to treat constipation. It acts on a particular serotonin receptor, called the serotonin 4 receptor. Researchers are interested in this receptor because understanding how it works in the brain may help us learn more about depression and could contribute to the development of new treatments in the future.
The purpose of this study is to investigate the effects of prucalopride in people experiencing low mood. We will compare prucalopride with a placebo (a treatment with no active medication) to find out whether activating the serotonin 4 receptor affects sleep and aspects of thinking, including memory, attention and decision making.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Cognitive symptoms are common in depression and can persist even when other symptoms of depression have improved. These difficulties can include impairments in memory, attention and executive function, and there remains a need for treatments that specifically target cognitive dysfunction associated with depression.
Evidence from preclinical and human experimental studies suggests that activation of the serotonin 4 receptor (5-HT4R) may represent a potential therapeutic approach for targeting cognitive symptoms in depression. The 5-HT4R is expressed in brain regions involved in learning and memory, and experimental studies have investigated whether selective activation of this receptor can influence cognitive processes relevant to depression.
Prucalopride is a selective 5-HT4R agonist. In previous human experimental studies, we have found evidence that prucalopride can influence cognitive processes, including learning and memory, in healthy volunteers and people who have recovered from depression. The present study extends this work by investigating the cognitive effects of prucalopride in people who are currently experiencing low mood.
The study will use an experimental medicine approach to examine the effects of 5-HT4R activation on cognitive processes relevant to depression. In addition, the study will investigate the effect of prucalopride on sleep architecture. Sleep will be assessed in the home environment using wearable chest patches capable of sleep staging.
The study will provide proof-of-concept evidence regarding the effects of 5-HT4R activation on cognition and sleep in people experiencing low mood. These data will inform the design and feasibility of a future randomised controlled trial evaluating prucalopride in people with depression and cognitive impairment.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Susannah Murphy, PhD
- Numer telefonu: +441865618313
- E-mail: susannah.murphy@psych.ox.ac.uk
Kopia zapasowa kontaktu do badania
- Nazwa: Finley T Watton, MBiomedSci Neurosciences
- Numer telefonu: +447593941882
- E-mail: finley.watton@psych.ox.ac.uk
Lokalizacje studiów
-
-
Oxfordshire
-
Oxford, Oxfordshire, Zjednoczone Królestwo, OX3 7JX
- Warneford Hospital
-
Główny śledczy:
- Susannah E Murphy, DPhil
-
Kontakt:
- Susannah Murphy, PhD
- Numer telefonu: +441865618313
- E-mail: susannah.murphy@psych.ox.ac.uk
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Aged between 18-65
- Male or female
- Participant is willing and able to give informed consent for participation in the research
- Body mass index in the range of 18-35 inclusive
- Current PHQ-9 score in the range of 9-15
Exclusion Criteria:
- Any current or previous episode of a severe mental illness, other than Depressive Disorder. Comorbid Anxiety disorders will be allowed, but not OCD or PTSD.
- A first degree relative diagnosed with Bipolar Affective Disorder Type 1 or Schizophrenia
- Body Mass Index outside the range of 18 to 35 inclusive
- Any significant current medical condition likely to interfere with conduct of the study or analysis of data
- Current use of psychoactive and / or medically significant medication as judged by a study medic, whether prescribed or bought over the counter (the contraceptive pill, the Depo-Provera injection or the progesterone implant will not result in exclusion)
- Ongoing psychopharmacological treatment for depression, including hypnotics (psychotherapy will be allowed as long as not newly-started in the last 6 weeks)
- High consumption of illicit substances to an extent that would make complying with study protocol challenging (including alcohol, caffeine, nicotine)
- Past history of dependence to illicit substances, and any consumption of illicit substances in the three months prior to the study
- Currently pregnant, trying to get pregnant, or breast feeding
- Current, or a significant history of, gastro-intestinal disorder or irritable bowel syndrome
- Known lactase deficiency or any other problem absorbing lactose, galactose, or glucose
- Participation in a study that involves the use of a medication or novel vaccine within the last three months
- Participation in a study using the same tasks in the last year
- Any physical (including visual and auditory) or language impairment that would make complying with the study protocol challenging, including yellow/blue colourblindness
- A head injury causing concussion or loss of consciousness within the last six months
- Moderate to high risk of suicide or self-harm
- Participant who is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Chief Investigator.
Additional Exclusion Criteria for Participants in the Sleep Study Cohort:
- Unable to undergo cardiac monitoring
- Unable to wear the sleep patch device for full monitoring period
- Implanted neurostimulator or pacemaker
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Prucalopride
Participants will receive daily oral prucalopride for 14 days. |
Prucalopride will be administered orally once daily for 14 days. Participants will receive 1 mg once daily on Days 1-2 and 2 mg once daily on Days 3-14. |
|
Komparator placebo: Placebo
Participants will receive daily oral placebo for 14 days. |
A matching placebo (lactose) will be administered orally once daily for 14 days. Participants will take one placebo capsule on Days 1-2 and two placebo capsules on Days 3-14, matching the dosing schedule of the prucalopride intervention. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Auditory Verbal Learning Test (AVLT)
Ramy czasowe: Day 14 (post-intervention)
|
Verbal learning and memory will be assessed using the Auditory Verbal Learning Test, including measures of immediate recall, delayed recall, and recognition memory. AVLT performance will be compared between prucalopride and placebo groups following the intervention. |
Day 14 (post-intervention)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Sleep outcomes measured using wearable sleep monitoring
Ramy czasowe: Baseline (Day 0) and Days 1-4 of the intervention
|
Sleep will be assessed using a wearable chest patch in a subset of participants (n=20 total, 10 per intervention group). Measures will include sleep duration, sleep quality and sleep staging. Sleep outcomes will be compared between the prucalopride and placebo groups. |
Baseline (Day 0) and Days 1-4 of the intervention
|
|
Digit Span Task
Ramy czasowe: Baseline and Day 14 (post-intervention)
|
Maximum digit span will be assessed as a measure of working memory and compared between the prucalopride and placebo groups |
Baseline and Day 14 (post-intervention)
|
|
Emotional Go/No-Go (EGNG)
Ramy czasowe: Day 14 (post-intervention)
|
Inhibitory control will be assessed using the EGNG task, including measures of commission errors, omission errors, and reaction time. Performance will be compared between prucalopride and placebo groups follwing the intervention. |
Day 14 (post-intervention)
|
|
Probabilistic Reversal Learning Task (PRL)
Ramy czasowe: Day 14 (post-intervention)
|
Cognitive flexibility and reward-based learning will be assessed using the PRL task, including measures such as response accuracy, reversal errors, and sensitivity to reward and punishment. Performance will be compared between prucalopride and placebo groups following the intervention. |
Day 14 (post-intervention)
|
|
Mnemonic Similarity Task (MST)
Ramy czasowe: Day 14 (post-intervention)
|
Pattern separation and recognition memory will be assessed using the MST. Performance will be compared between the prucalopride and placebo groups following the intervention. |
Day 14 (post-intervention)
|
|
Serial Addition Task (SAT)
Ramy czasowe: Day 14 (post-intervention)
|
Working memory will be assessed using the SAT. Performance will be compared between the prucalopride and placebo groups following the intervention |
Day 14 (post-intervention)
|
|
Matrix Span Task
Ramy czasowe: Baseline and Days 2, 3, 5, 6, 8, 10, 11 and 13 of the 14-day intervention.
|
Visual working memory assessed using the Matrix Span Task, administered remotely via the NeuroUX app. Performance (accuracy/reaction time) will be compared between prucalopride and placebo groups. |
Baseline and Days 2, 3, 5, 6, 8, 10, 11 and 13 of the 14-day intervention.
|
|
Variable Difficulty List Memory Test (VDLMT)
Ramy czasowe: Baseline and Days 1, 2, 4, 6, 7, 9, 11, 12 and 14 of the 14-day intervention.
|
Verbal learning and recognition memory will be assessed using the VDLMT, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups. |
Baseline and Days 1, 2, 4, 6, 7, 9, 11, 12 and 14 of the 14-day intervention.
|
|
N-Back Test
Ramy czasowe: Baseline and Days 1, 3, 4, 6, 8, 9, 11, 13 and 14 of the 14-day intervention.
|
Working memory will be assessed using the 2-back version of the N-back task, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups. |
Baseline and Days 1, 3, 4, 6, 8, 9, 11, 13 and 14 of the 14-day intervention.
|
|
Digit Symbol Substitution Task (DSST)
Ramy czasowe: Baseline and Days 1, 3, 5, 7, 8, 10, 12 and 13 of the 14-day intervention.
|
Processing speed will be assessed using the DSST, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups. |
Baseline and Days 1, 3, 5, 7, 8, 10, 12 and 13 of the 14-day intervention.
|
|
Quick Tap 2 Test
Ramy czasowe: Baseline and Days 2, 4, 5, 7, 9, 10, 12 and 14 of the 14-day intervention.
|
Response inhibition will be assessed using the Quick Tap 2 test, a go/no-go task administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups. |
Baseline and Days 2, 4, 5, 7, 9, 10, 12 and 14 of the 14-day intervention.
|
|
Paired Associates Learning (PAL)
Ramy czasowe: Day 14 (post-intervention)
|
Verbal associative and episodic memory will be assessed using the PAL task. Performance will be compared between the prucalopride and placebo groups. |
Day 14 (post-intervention)
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
State Subjective Cognition Scale (SSCS)
Ramy czasowe: Baseline and daily during the 14-day intervention.
|
Subjective cognitive functioning will be assessed using the State Subjective Cognition Scale (SSCS). Responses will be compared between the prucalopride and placebo groups. |
Baseline and daily during the 14-day intervention.
|
|
Positive and Negative Affect Schedule (PANAS)
Ramy czasowe: Baseline and daily during the 14-day intervention.
|
Positive and negative affect will be assessed using the PANAS. Scores will be compared between the prucalopride and placebo groups. |
Baseline and daily during the 14-day intervention.
|
|
Patient Health Questionnaire-9 (PHQ-9)
Ramy czasowe: Baseline, Day 7 and Day 14 of the intervention
|
Depressive symptoms will be assessed using the PHQ-9. Scores will be compared between the prucalopride and placebo groups. |
Baseline, Day 7 and Day 14 of the intervention
|
|
Perceived Deficits Questionnaire (PDQ)
Ramy czasowe: Baseline, Day 7 and Day 14 of the intervention
|
Subjective cognitive difficulties will be assessed using the PDQ. Scores will be compared between the prucalopride and placebo groups. |
Baseline, Day 7 and Day 14 of the intervention
|
|
Generalized Anxiety Disorder-7 (GAD-7)
Ramy czasowe: Baseline, Day 7 and Day 14 of the intervention.
|
Anxiety symptoms will be assessed using the GAD-7. Scores will be compared between the prucalopride and placebo groups. |
Baseline, Day 7 and Day 14 of the intervention.
|
|
Temporal Experience of Pleasure Scale (TEPS)
Ramy czasowe: Baseline, Day 7 and Day 14 of the intervention.
|
Anticipatory and consummatory pleasure will be assessed using the TEPS. Scores will be compared between the prucalopride and placebo groups. |
Baseline, Day 7 and Day 14 of the intervention.
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Susannah E Murphy, DPhil, Department of Psychiatry, University of Oxford
Publikacje i pomocne linki
Publikacje ogólne
- Ahern E, White J, Slattery E. Change in Cognitive Function over the Course of Major Depressive Disorder: A Systematic Review and Meta-analysis. Neuropsychol Rev. 2025 Mar;35(1):1-34. doi: 10.1007/s11065-023-09629-9. Epub 2024 Feb 5.
- De Giorgi R, Waters S, Gillespie AL, Quinton AMG, Colwell MJ, Murphy SE, Cowen PJ, Harmer CJ. Effects of 28-day simvastatin administration on emotional processing, reward learning, working memory, and salivary cortisol in healthy participants at-risk for depression: OxSTEP, an online experimental medicine trial. Psychol Med. 2025 May 22;55:e155. doi: 10.1017/S0033291725001187.
- Colwell MJ, Tagomori H, Chapman S, Gillespie AL, Cowen PJ, Harmer CJ, Murphy SE. Pharmacological targeting of cognitive impairment in depression: recent developments and challenges in human clinical research. Transl Psychiatry. 2022 Nov 17;12(1):484. doi: 10.1038/s41398-022-02249-6.
- de Cates AN, Harmer CJ, Harrison PJ, Cowen PJ, Emmanuel A, Travis S, Murphy SE, Taquet M. Association between a selective 5-HT4 receptor agonist and incidence of major depressive disorder: emulated target trial. Br J Psychiatry. 2024 Sep;225(3):371-378. doi: 10.1192/bjp.2024.97.
- Singh S, Strong R, Xu I, Fonseca LM, Hawks Z, Grinspoon E, Jung L, Li F, Weinstock RS, Sliwinski MJ, Chaytor NS, Germine LT. Ecological Momentary Assessment of Cognition in Clinical and Community Samples: Reliability and Validity Study. J Med Internet Res. 2023 Jun 2;25:e45028. doi: 10.2196/45028.
- de Cates AN, Wright LC, Martens MAG, Gibson D, Turkmen C, Filippini N, Cowen PJ, Harmer CJ, Murphy SE. Deja-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task. Transl Psychiatry. 2021 Oct 4;11(1):497. doi: 10.1038/s41398-021-01568-4.
- Murphy SE, Wright LC, Browning M, Cowen PJ, Harmer CJ. A role for 5-HT4 receptors in human learning and memory. Psychol Med. 2020 Dec;50(16):2722-2730. doi: 10.1017/S0033291719002836. Epub 2019 Oct 16.
- Murphy SE, de Cates AN, Gillespie AL, Godlewska BR, Scaife JC, Wright LC, Cowen PJ, Harmer CJ. Translating the promise of 5HT4 receptor agonists for the treatment of depression. Psychol Med. 2021 May;51(7):1111-1120. doi: 10.1017/S0033291720000604. Epub 2020 Apr 3.
- Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011 Jun;41(6):1165-74. doi: 10.1017/S0033291710001911. Epub 2010 Oct 8.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- PROMOTE (2544373)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Anonymised individual participant data (IPD) that underlie the results reported in publications arising from this study will be available to researchers upon request, subject to appropriate ethical, data protection and institutional requirements
Ramy czasowe udostępniania IPD
Available following the publication of the study results
Kryteria dostępu do udostępniania IPD
Available to researchers on request, subject to approal by the study team/institution and applicable ethical and data protection requirements
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .